Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive

Sep 07 2018

• By Sue Sutter

FDA entrance sign 2016

Related Content

FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

May 23 2016

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Sep 20 2017

Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior

Aug 28 2018

FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models

Jul 19 2018

Related Companies

Novartis AG

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Celltrion, Inc.

Pfizer Inc.

Samsung Bioepis Co., Ltd.

Merck & Co., Inc.

Johnson & Johnson

Viatris Inc.

AbbVie Inc.

Additional Topics

United States Biosimilars Biologics Pricing Debate Regulation BioPharmaceutical

More from Drug Pricing

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window